Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucamtasutab plus targeted therapy as neoadjuvant treatment for rare‑mutation NSCLC
ChiCTR2600125945Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of lucamtasutab in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Major pathological response (MPR) rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
lucamtasutab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600125945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125945.